The Enterprise Value as of November 2024 (TTM) for Lineage Cell Therapeutics, Inc. (LCTX) is 131.69M

According to Lineage Cell Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 131.69M. This represents a change of -26.21% compared to the average of 178.47M of the last 4 quarters.

Lineage Cell Therapeutics, Inc. (LCTX) Historical Enterprise Value (quarterly & annually)

How has LCTX Enterprise Value performed in the past?

The mean historical Enterprise Value of Lineage Cell Therapeutics, Inc. over the last ten years is 220.34M. The current 131.69M Enterprise Value has changed 5.88% with respect to the historical average. Over the past ten years (40 quarters), LCTX's Enterprise Value was at its highest in in the June 2021 quarter at 395.76M. The Enterprise Value was at its lowest in in the December 2018 quarter at 94.24M.

Lineage Cell Therapeutics, Inc. (LCTX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Lineage Cell Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lineage Cell Therapeutics, Inc. (LCTX) Average Enterprise Value

How has LCTX Enterprise Value performed in the past?

The current Enterprise Value of Lineage Cell Therapeutics, Inc. (LCTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Lineage Cell Therapeutics, Inc. (LCTX) Enterprise Value vs. Peers

How is LCTX’s Enterprise Value compared to its peers?

Lineage Cell Therapeutics, Inc.’s Enterprise Value is greater than MAIA Biotechnology, Inc. (57.27M), less than Armata Pharmaceuticals, Inc. (204.77M), greater than Frequency Therapeutics, Inc. (-29354368.00), greater than Portage Biotech Inc. (1.96M), greater than AgeX Therapeutics, Inc. (19.70M), greater than Cadrenal Therapeutics, Inc. Common Stock (10.21M), greater than ImmuCell Corporation (42.63M), less than Oxford Nanopore Technologies plc (1.20B), less than Replimune Group, Inc. (745.52M), greater than Nuvectis Pharma, Inc. (99.58M), greater than Lyra Therapeutics, Inc. (22.05M), greater than Kronos Bio, Inc. (14.20M), less than Gossamer Bio, Inc. (312.50M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), less than Nuvation Bio Inc. (1.02B), greater than Ovid Therapeutics Inc. (70.41M), greater than NextCure, Inc. (21.96M), greater than Connect Biopharma Holdings Limited (-43544162.00), greater than Spero Therapeutics, Inc. (11.13M), greater than Bolt Biotherapeutics, Inc. (38.25M), less than Coherus BioSciences, Inc. (216.29M), less than Gracell Biotechnologies Inc. (5.47B),

Build a custom stock screener for Lineage Cell Therapeutics, Inc. (LCTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lineage Cell Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lineage Cell Therapeutics, Inc. (LCTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lineage Cell Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.